Antiendothelial cell antibody levels in patients with masked hypertension

International Journal of Cardiology

Volumn 130, Issue 3, 2008, Pages 405-408

  Papadopoulos, D P ^a   Makris, T K ^a   Papazachou, U ^a   Daskalaki, M ^a   Sanidas, E ^a   Votteas, V E ^a  

^a LAIKO GENERAL HOSPITAL   (Greece)

Author keywords

Antiendothelial cell antibody hypertension; Hypertension; Masked hypertension

Indexed keywords

ENDOTHELIAL CELL ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M;

ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; BLOOD PRESSURE MONITORING; BODY MASS; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; ATHEROSCLEROSIS; AUTOANTIBODIES; BLOOD PRESSURE; ENDOTHELIAL CELLS; FEMALE; HUMANS; HYPERTENSION; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MALE; MIDDLE AGED; RISK FACTORS; SEROEPIDEMIOLOGIC STUDIES;

EID: 55549091392     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2007.08.122     Document Type: Article

References (27)

1. Pickering T.G., Shimbo D., and Haas D. Ambulatory blood-pressure monitoring. N Engl J Med 354 22 (2006) 2368-2374
2. McKay D.W., Myers M.G., Bolli P., and Chockalingam A. Masked hypertension: a common but insidious presentation of hypertension. Can J Cardiol 22 7 (2006) 617-620
3. Mancia G., Sega R., Bravi C., et al. Ambulatory blood pressure normality: results from the PAMELA study. J Hypertens 12 Pt 1 (1995) 1377-1390
4. Waeber B. What is behind masked hypertension?. Rev Med Suisse Romande 1 32 (2005) 2089-2091
5. Pickering T.G. Effects of stress and behavioral interventions in hypertension: what is masked hypertension?. J Clin Hypertens (Greenwich) 5 2 (2003) 171-174 [176]
6. Palatini P. Masked hypertension: how can the condition be detected?. Blood Press Monit 9 6 (2004) 297
7. Mancia G., Carugo S., Grassi G., et al. Prevalence of left ventricular hypertrophy in hypertensive patients without and with blood pressure control: data from the PAMELA population. Hypertension 39 3 (2002) 744-749
8. Sega R., Trocino G., Lanzarotti A., et al. Alterations of cardiac structure in patients with isolated office, ambulatory, or home hypertension: data from the general population PAMELA Study. Circulation 104 12 (2001) 1385-1392
9. Tomiyama M., Horio T., Kamide K., et al. Reverse white-coat effect as an independent risk for left ventricular concentric hypertrophy in patients with treated essential hypertension. J Hum Hypertens 21 3 (Mar 2007) 212-219
10. Hara A., Ohkubo T., Kikuya M., et al. Detection of carotid atherosclerosis in individuals with masked hypertension and white-coat hypertension by self-measured blood pressure at home: The Ohasama Study. J Hypertens 25 2 (2007) 321-327
11. Pierdomenico S.D., Lapenna D., Bucci A., et al. Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant, and true resistant hypertension. Am J Hypertens 18 11 (2005) 1422-1428
12. Mancia G., Facchetti R., Bombelli M., Grassi G., and Sega R. Long-term risk of mortality associated with selective and combined elevation in office, home, and ambulatory blood pressure. Hypertension 47 5 (2006) 846-853
13. Tomiyama M., Horio T., Yoshii M., et al. Masked hypertension and target organ damage in treated hypertensive patients. Am J Hypertens 19 9 (2006) 880-886
14. Kato T., Horio T., Tomiyama M., et al. Reverse white-coat effect as an independent risk for microalbuminuria in treated hypertensive patients. Nephrol Dial Transplant 22 3 (2007) 911-916
15. Kluz J., and Adamiec R. The role of anti-endothelial cell antibodies in the pathogenesis of atherosclerosis and diabetic angiopathy. Przegl Lek 60 11 (2003) 751-754
16. Alessandri C., Bombardieri M., and Valesini G. Pathogenic mechanisms of anti-endothelial cell antibodies (AECA): their prevalence and clinical relevance. Adv Clin Chem 42 (2006) 297-326
17. European Society of Hypertension-European Society of Cardiology Guidelines Committee. European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 6 (2003) 1011-1053
18. Seidell J.C., Cigolini M., Deslypere J.P., Charzewska J., Ellsinger B.M., and Cruz A. Body fat distribution in relation to physical activity and smoking habits in 38 year old European men. Am J Epidemiol 133 (1991) 257-265
19. Chobanian A.V., Bakris G., Black H., et al. The National High Blood Pressure Education Program Coordinating Committee. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42 (2003) 1206-1252
20. Mancia G., Sega R., Bravi C., et al. Ambulatory blood pressure normality: results from the PAMELA study. J Hypertens 12 Pt 1 (1995) 1377-1390
21. Farsi A., Domeneghetti M.P., Brunelli T., et al. Activation of the immune system and coronary artery disease: the role of anti-endothelial cell antibodies. Atherosclerosis 154 2 (2001) 429-436
22. Geshi T., Kuno Y., Kase S., and Mori N. H Anti-endothelial cell antibody in preeclampsia: clinical findings and serum cytotoxicity to endothelial cell. Yamamoto. Nihon Rinsho Meneki Gakkai Kaishi 21 5 (1998) 191-197
23. Nityanand S., Bergmark C., de Faire U., Swedenborg J., Holm G., and Lefvert A.K. Antibodies against endothelial cells and cardiolipin in young patients with peripheral atherosclerotic disease. J Intern Med 238 5 (1995) 437-443
24. Papadopoulos D.P., Makris T.K., Krespi P., et al. Antiendothelial cell antibody levels in healthy normotensives with high normal blood pressure. Clin Exp Hypertens 28 8 (Nov 2006) 663-667
25. Portig I., Beck V., Pankuweit S., and Maisch B. Antiendothelial antibodies in sera of patients with infective endocarditis. Basic Res Cardiol 96 1 (2001) 75-81
26. Belizna C., and Tervaert J.W. Specificity, pathogenecity, and clinical value of antiendothelial cell antibodies. Semin Arthritis Rheum 27 2 (1997) 98-109
27. Van Haelst P.L., Kobold A.C., van Doormaal J.J., and Tervaert J.W. AECA and ANCA in patients with premature atherosclerosis. Int Rev Immunol 21 1 (2002) 19-26